跳至主要内容
临床试验/NCT00272103
NCT00272103已完成2 期

A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Dose Finding Study in 4 Parallel Groups to Establish the Efficacy and Safety of an Eight Week Treatment With Itopride Three Times Daily Compared to Placebo in Patients Suffering From Functional Dyspepsia

Royal Adelaide Hospital1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2000年12月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
500
试验地点
1
主要终点
After 8 weeks of treatment:

研究概览

简要总结

This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the treatment of patients with functional dyspepsia.

The study will test in patients with functional dyspepsia the hypothesis that itopride is superior to placebo with regard to the improvement of symptoms.

详细描述

Treatment of patients with functional dyspepsia remains unsatisfactory. We will assess the efficacy of Itopride, a D2 antagonist with acetylcholinesterase effects in patients with functional dyspepsia.

Patients with functional dyspepsia will be randomized to Itopride (50, 100 or 200 mg tid) or placebo. After 8 weeks of treatment, three primary efficacy endpoints will be analyzed: a) change of the severity of functional dyspepsia symptoms (assessed by the Leeds Dyspepsia Questionnaire), b) patient's global assessment of efficacy (proportion of patients symptom-free or markedly improved)and c) improvement of pain and/or fullness by at least one grade on a 5-grade scale.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 95 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of functional dyspepsia (Rome criteria) -

排除标准

  • •structural or biochemical abnormalities explaining the symptoms, concomitant symptoms of gastroesophageal reflux disease or irritable bowel syndrome dominating the clinical picture

结局指标

主要结局

After 8 weeks of treatment:

Change of the severity of functional dyspepsia symptoms assessed by the Leeds Dyspepsia Questionnaire)

Patient's global assessment of efficacy (proportion of patients symptom-free or markedly improved)

Improvement of pain and/or fullness by at least one grade on a 5-grade scale.

次要结局

  • Safety parameters

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验